ADVFN Logo

Hot Features

Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.

AGEN Agenus Inc

0,5607
0,0043 (0,77%)
29 Mar 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Agenus Inc AGEN NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
0,0043 0,77% 0,5607 00:45:32
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
0,5564 0,5505 0,574 0,58 0,5564
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
14/3/202412:30BWAgenus Reports Fourth Quarter and Full Year 2023 Results
06/3/202413:30BWAgenus Announces Preclinical Data on BMS-986442 (AGEN1777)..
05/3/202422:30BWAgenus Reports Inducement Grants Under Nasdaq Listing Rule..
29/2/202422:50EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
29/2/202413:30BWAgenus to Provide Corporate Update and Fourth Quarter & Full..
26/2/202422:24EDGAR2Form DEF 14A - Other definitive proxy statements
26/2/202413:30BWAgenus to Participate in Leerink Partners Global Biopharma..
15/2/202414:02EDGAR2Form PRE 14A - Other preliminary proxy statements
15/2/202414:00EDGAR2Form 8-K - Current report
15/2/202413:02PRNUSGinkgo Bioworks and SaponiQx Awarded MCDC Contract to..
14/2/202414:33EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
12/2/202413:00EDGAR2Form 5 - Annual statement of changes in beneficial ownership..
09/2/202423:11EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
31/1/202414:00EDGAR2Form 8-K - Current report
31/1/202413:30BWAgenus to Participate in Oppenheimer 34th Annual Healthcare..
22/1/202415:59BWBotensilimab/Balstilimab Breakthrough Data Presented at..
22/1/202413:30BWBotensilimab/Balstilimab Breakthrough Data Presented at..
05/1/202422:30BWAgenus Reports Inducement Grants Under Nasdaq Listing Rule..
04/1/202413:30BWAgenus to Participate in B. Riley Healthcare Conference
04/1/202412:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202412:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202412:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/12/202313:30BWBotensilimab/Balstilimab Data in Neoadjuvant Colorectal..
11/12/202313:30BWAgenus to Receive $25 Million Milestone Payment from Bristol..
08/12/202322:15EDGAR2Form 8-K - Current report
17/11/202322:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/11/202322:11EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/11/202312:30EDGAR2Form 8-K - Current report
07/11/202312:30BWAgenus Reports Third Quarter 2023 Results
26/10/202315:05BWAgenus to Provide Third Quarter 2023 Financial Report and..
22/10/202318:00BWAgenus Unveils New and Updated Botensilimab Data in..
21/10/202310:15BWESMO 2023: Agenus’ Botensilimab/Balstilimab Combination..
16/10/202323:49EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/10/202313:30BWAgenus Completes Enrollment in Randomized Phase 2 Clinical..
06/10/202322:26EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/10/202313:30BWAgenus To Host BOT/BAL Program Update at ESMO 2023
04/10/202323:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/10/202323:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/10/202323:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/9/202322:30BWAgenus Reports Inducement Grants Under Nasdaq Listing Rule..
31/8/202323:53EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/8/202323:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/8/202313:30BWAgenus to Participate in September Investor Conferences
23/8/202314:00EDGAR2Form 8-K - Current report
23/8/202314:00BWAgenus Prioritizes Resources to Accelerate Registration and..
09/8/202314:30BWSaponiQx Announces Breakthrough in Scaling Up of STIMULON™..
08/8/202322:04EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/8/202313:30EDGAR2Form 8-K - Current report
08/8/202313:30BWAgenus Reports Second Quarter 2023 Results
28/7/202313:30BWAgenus Botensilimab/Balstilimab Data Update in Sarcomas..

Dernières Valeurs Consultées

Delayed Upgrade Clock